A model to predict delivery of reduced chemotherapy dose intensity in the first three cycles of treatment among patients with non-Hodgkin's lymphoma and breast cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 6100-6100
Author(s):  
V. Caggiano ◽  
V. A. Morrison ◽  
M. Fridman ◽  
D. J. Delgado
Keyword(s):  
Breast Cancer ◽  
Hodgkin’S Lymphoma ◽  
Dose Intensity ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Chemotherapy Dose ◽  
Chemotherapy Dose Intensity

scholarly journals CXCL12 rs1801157 polymorphism in patients with breast cancer, hodgkin's lymphoma, and non-hodgkin's lymphoma

2009 ◽  
Vol 23 (6) ◽  
pp. 387-393 ◽  
Author(s):  
Karen Brajão de Oliveira ◽  
Julie Massayo Maeda Oda ◽  
Julio Cesar Voltarelli ◽  
Thiago Franco Nasser ◽  
Mario Augusto Ono ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.

1995 ◽  
Vol 13 (10) ◽  
pp. 2530-2539 ◽  
Author(s):  
P Sonneveld ◽  
M de Ridder ◽  
H van der Lelie ◽  
K Nieuwenhuis ◽  
H Schouten ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Hodgkin’S Lymphoma ◽  
Dose Intensity ◽  
Hodgkin's Lymphoma ◽  
Phase Iii ◽  
Serum Lactate Dehydrogenase ◽  
High Grade ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Disease Free

PURPOSE AND METHODS A prospective, randomized, multicenter phase III trial was performed to investigate the feasibility of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy in elderly patients ( > or = 60 years) with advanced non-Hodgkin's lymphoma (NHL) of intermediate- and high-grade malignancy, and to compare the tolerance and efficacy of doxorubicin versus mitoxantrone (CHOP v CNOP). RESULTS Of 157 enrolled patients, 148 were eligible and 145 were assessable for response. Thirty-one percent of CNOP and 45% of CHOP patients completed six cycles without dose reduction. The cumulative normalized dose-intensity (NDI) was 92% with CHOP and 90% with CNOP after six cycles. The overall complete response (CR) rates were 49% and 31% in CHOP- and CNOP-treated patients, respectively (P = .03). Survival with CNOP was significantly worse as compared with CHOP (P = .03). Lymphoma-specific survival was significantly better in CHOP-treated patients (P = .034) At 3 years, 42% of CHOP and 26% of CNOP patients were alive. Additional unfavorable prognostic factors at diagnosis were high serum lactate dehydrogenase (LDH) level, bulky mass, and low performance status, but not age. The median disease-free intervals of complete responders were 27 (CHOP) and 15 (CNOP) months, respectively. Considering the complete group of patients, at 3 years 17% of CHOP and 13% of CNOP patients were alive and disease-free (P = .12). Common toxicity criteria (CTC) grade > or = 2 with CNOP and CHOP was not different. CONCLUSION CHOP is well tolerated in elderly patients with advanced intermediate- or high-grade NHL and its NDI is not seriously impaired. Treatment with CHOP (doxorubicin) results in better CR and survival rates than CNOP (mitoxantrone). CHOP should be recommended for elderly patients with high-risk NHL.

Sign in / Sign up

Export Citation Format

Share Document